Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/79941
Citations
Scopus Web of ScienceĀ® Altmetric
?
?
Type: Journal article
Title: Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors
Author: Gillis, J.
Selth, L.
Centenera, M.
Townley, S.
Sun, S.
Plymate, S.
Tilley, W.
Butler, L.
Citation: Oncotarget, 2013; 4(5):691-704
Publisher: Impact Journals LLC
Issue Date: 2013
ISSN: 1949-2553
1949-2553
Statement of
Responsibility: 
Joanna L. Gillis, Luke A. Selth, Margaret M. Centenera, Scott L. Townley, Shihua Sun, Stephen R. Plymate, Wayne D. Tilley and Lisa M. Butler
Abstract: The development of lethal, castration resistant prostate cancer is associated with adaptive changes to the androgen receptor (AR), including the emergence of mutant receptors and truncated, constitutively active AR variants. AR relies on the molecular chaperone HSP90 for its function in both normal and malignant prostate cells, but the requirement for HSP90 in environments with aberrant AR expression is largely unknown. Here, we investigated the efficacy of three HSP90 inhibitors, 17-AAG, HSP990 and AUY922, against clinically-relevant AR missense mutants and truncated variants. HSP90 inhibition effectively suppressed the signaling of wild-type AR and all AR missense mutants tested. By contrast, two truncated AR variants, AR-V7 and ARv567es, exhibited marked resistance to HSP90 inhibitors. Supporting this observation, nuclear localization of the truncated AR variants was not affected by HSP90 inhibition and AR variant:HSP90 complexes could not be detected in prostate cancer cells. Interestingly, HSP90 inhibition resulted in accumulation of AR-V7 and ARv567es in both cell lines and human tumor explants. Despite the apparent independence of AR variants from HSP90 and their treatment-associated induction, the growth of cell lines with endogenous or enforced expression of AR-V7 or ARv567es remained highly sensitive to AUY922. This study demonstrates that functional AR variant signaling does not confer resistance to HSP90 inhibition, yields insight into the interaction between AR and HSP90 and provides further impetus for the clinical application of HSP90 inhibitors in advanced prostate cancer.
Keywords: Androgen receptor; variant; HSP90; HSP90 inhibitor; prostate cancer
Rights: This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
RMID: 0020130982
DOI: 10.18632/oncotarget.975
Published version: http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=975
Appears in Collections:Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_79941.pdfPublished version1.99 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.